专家谈失眠治疗：患者不需要“谈药色变”

Core Insights - The forum highlighted the increasing prevalence of insomnia in China, with a sleep disturbance rate of 48.5% among individuals aged 18 and above, and the number of adults suffering from insomnia rising from 250 million in 2016 to 270 million in 2020, projected to reach 330 million by 2030 [2][3] Group 1: Insomnia Treatment Developments - The approval of two innovative insomnia medications in China marks the beginning of the Dual Orexin Receptor Antagonist (DORA) era in insomnia treatment [1][4] - Traditional insomnia medications have significant side effects, including daytime drowsiness and cognitive decline, while DORA medications offer effective treatment with improved safety profiles [4][6] Group 2: Market Opportunities - The sleep economy in China is projected to grow from 534.93 billion yuan in 2024 to 658.68 billion yuan by 2027, indicating a strong growth trend [5] - The DORA drug market is still developing, with only three DORA insomnia medications approved globally, and several Chinese pharmaceutical companies are actively entering this market [6]